COLUMBIA, Md., Jan. 29 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (NASDAQ:MATK) announced today that Mead Johnson Nutritionals(R) Canada has introduced a new DHA- and ARA-fortified infant formula to its line of Enfamil(R) products. The new formula, Enfamil A+, contains Martek's proprietary blend of plant-derived docosahexaenoic acid (DHA) and arachidonic acid (ARA). Enfamil A+ is the first and only formula in Canada to contain these nutrients.
DHA and ARA, two nutrients that are key building blocks of an infant's brain and visual system, are naturally present in breast milk. Clinical studies have demonstrated numerous benefits for those infants receiving DHA and ARA-supplemented formula. Martek's blend of DHA and ARA is the only source of these nutrients that has been reviewed by Health Canada and cleared for use in Canadian infant formula. Previously, this same blend of DHA and ARA was reviewed by the United States Food and Drug Administration (FDA) and cleared for use in U.S. infant formula.
"Martek is pleased with Mead Johnson's expansion of its DHA and ARA formula," stated Henry "Pete" Linsert, Jr., Chairman and CEO of Martek. "It's a great day for Canadian babies."
Enfamil A+ is currently available in stores throughout Canada. Currently, infant formulas containing Martek's oils are sold in over 60 countries by various infant formula manufacturers, all of which are licensees of Martek.
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.